A study of phamaceutical policies in the EU

Alan Earl‐Slater

Policy Studies, 1997, vol. 18, issue 3-4, 251-267

Abstract: This paper identifies and explores some of the major current policy developments in the EU pharmaceutical environment. The policies considered are: the new pan‐EU drug licensing system; changes to the rules of the system over time; the BSE crisis as it affects Pharmaceuticals; member states' pricing and reimbursement policies and the EU Directive; companies calling government policy into account; governments calling companies policies into account; and the new working parties addressing issues on a single EU pharmaceutical market.

Date: 1997
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1080/01442879708423736 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:taf:cposxx:v:18:y:1997:i:3-4:p:251-267

Ordering information: This journal article can be ordered from
http://www.tandfonline.com/pricing/journal/cpos20

DOI: 10.1080/01442879708423736

Access Statistics for this article

Policy Studies is currently edited by Toby James

More articles in Policy Studies from Taylor & Francis Journals
Bibliographic data for series maintained by Chris Longhurst ().